Mesoblast shares are back in the red on Tuesday. Here’s why

Mesoblast Ltd shares dipped slightly despite reporting strong quarterly sales for its flagship product, Ryoncil, which generated US$30.3 million in the March quarter and nearly US$100 million cumulatively since launch. The market’s subdued reaction suggests that much of the optimism had already been priced in earlier when the shares hit a 52-week high, and investors might be awaiting further major clinical or commercial updates. Attention is now on whether the company can sustain sales growth to meet its FY2026 net revenue guidance and improve margins.